BDC in the News

University of Colorado Anschutz Medical Campus

Anschutz

Barbara Davis Center in the News

FEATURED: Studies Find Better Glucose Control When Using Continuous Glucose Monitoring Devices

Continuous Glucose Monitors (CGM) are small devices that continually measure glucose levels under the skin, and transmit this information to a wireless device such as a receiver or cell phone. Two large multi-center studies recently published in the Journal of the American Medical Association (JAMA) tested if these devices improved glycemic control or reduced incidence of life-threatening low glucose levels in two very unique populations: adolescents and older adults living with type 1 diabetes. The CITY (CGM Intervention in Teens and Young Adults with type 1 diabetes) trial was a six month randomized controlled trial that showed that CGM helps adolescents and young adults manage their type 1 diabetes more effectively, compared with daily use of blood glucose finger-stick testing. The CGM users saw significant reductions in their hemoglobin A1C levels and less time spent with severe high and low blood glucose levels. Barbara Davis Center clinical and research staffs, including investigators Laurel Messer, PhD, Viral Shah, MD and Paul Wadwa, MD, were involved in the conduct of both landmark clinical trials.

Links to the two press releases are found here:

Release 1 - "Study Finds Better Glucose Control for Young People Using Continuous Monitoring Devices"

Release 2 - "Continuing Glucose Monitoring Reduces Hypoglycemia in Older Adults With Type 1 Diabetes"

Links to the two articles are found here:

https://jamanetwork.com/journals/jama/article-abstract/2767160

https://jamanetwork.com/journals/jama/article-abstract/2767159

Artificial pancreas effectively controls type 1 diabetes in children age 6 and up

The artificial pancreas is an “all-in-one” diabetes management system that tracks blood glucose levels using a continuous glucose monitor and automatically delivers insulin when needed

A clinical trial at the Barbara Davis Center for Childhood Diabetes at the University of Colorado Anschutz Medical Center and three other pediatric diabetes centers in the United States has found that a new artificial pancreas system — which automatically monitors and regulates blood glucose levels — is safe and effective at managing blood glucose levels in children as young as age six with type 1 diabetes. The trial was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health. Results from the trial were published August 26 in the New England Journal of Medicine.

	Dr. Andrea Gerard Gonzalez discusses how for diabetes patients, new health threats and cost concerns surface during coronavirus. Full Story >>
	NFL player, Uchenna Nwosu visits the Barbara Davis Center and plays football with kids Full Story >>
	Dr. Aaron Michels' Research using Methyldopa for Prevention of T1D. Full Story>>
	Dr. Richard Benninger and Richard Ramirez use ultrasound technology to track T1D Full Story>>
	Dr. Satish Garg talks about first-ever oral drug for T1D Full Story>>
	Participating in T1D Trials, The Value of Knowing Full Story>>

	"Just ASK to Know:" One family's journey before and after screening for T1D Full Story>>

University of Colorado Anschutz Medical Campus

Anschutz

Locations

Tools

Schools and Colleges

CU Denver

CU Anschutz Medical Campus

Barbara Davis Center for Childhood Diabetes

School of Medicine

Free CU Anschutz COVID-19 Antibody Tests to Fuel Diabetes Study

Artificial Pancreas System Better Controls Blood Glucose Levels Than Current Technology

One-Hour OGTT As Accurate As Two Hr OGTT For Diabetes Detection, Finds Study

Barbara Davis Center in the News

Dr. Andrea Gerard Gonzalez discusses how for diabetes patients, new health threats and cost concerns surface during coronavirus.

Full Story >>

NFL player, Uchenna Nwosu visits the Barbara Davis Center and plays football with kids

Full Story >>

Dr. Aaron Michels' Research using Methyldopa for Prevention of T1D.

Full Story>>

Dr. Richard Benninger and Richard Ramirez use ultrasound technology to track T1D

Full Story>>

Dr. Satish Garg talks about first-ever oral drug for T1D

Full Story>>

Participating in T1D Trials, The Value of Knowing

Full Story>>

"Just ASK to Know:" One family's journey before and after screening for T1D

Full Story>>